We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cardinal Health (CAH) Tops Q3 Earnings, Miss on Revenues
Read MoreHide Full Article
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its third-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings rose 7% on a year-over-year basis to $1.53 per share. It also managed to outpace the Zacks Consensus Estimate of $1.46.
Revenues: Revenues increased 4% on a year-over-year basis to $31.8 billion. It however came below the Zacks Consensus Estimate of $32.5 billion.
Key Stats: Pharmaceutical revenues surged 3% to $28.4 billion while revenues from Medical segment increased 9% to $3.4 billion in the quarter.
Major Factors: Pharmaceutical segment revenues increased due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers. Higher contributions from net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Check back later for our full write up on this Cardinal Health earnings report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Cardinal Health (CAH) Tops Q3 Earnings, Miss on Revenues
Cardinal Health Inc. (CAH - Free Report) is a healthcare services company engaged in providing pharmaceutical and medical products and services in the United States and International markets. The company primarily operates in two segments, Pharmaceutical and Medical.
Currently, Cardinal Health has a Zacks Rank #4 (Sell) but that could change following its third-quarter fiscal 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings: Cardinal Health’s adjusted earnings rose 7% on a year-over-year basis to $1.53 per share. It also managed to outpace the Zacks Consensus Estimate of $1.46.
Revenues: Revenues increased 4% on a year-over-year basis to $31.8 billion. It however came below the Zacks Consensus Estimate of $32.5 billion.
Key Stats: Pharmaceutical revenues surged 3% to $28.4 billion while revenues from Medical segment increased 9% to $3.4 billion in the quarter.
Cardinal Health, Inc. Price and EPS Surprise
Cardinal Health, Inc. Price and EPS Surprise | Cardinal Health, Inc. Quote
Major Factors: Pharmaceutical segment revenues increased due to strong growth from the Specialty business and higher number of Pharmaceutical Distribution business customers. Higher contributions from net new and existing customers were primarily responsible for the growth in Medical segment revenues.
Check back later for our full write up on this Cardinal Health earnings report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>